Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 218Rectal Neoplasms 133Stomach Neoplasms 111Colonic Neoplasms 101Pancreatic Neoplasms 81Neoplasm Metastasis 57Esophageal Neoplasms 48Neoplasms 31Adenocarcinoma Of Esophagus 23Adenocarcinoma 21Carcinoma, Hepatocellular 20Carcinoma, Non-Small-Cell Lung 16Biliary Tract Neoplasms 16Gallbladder Neoplasms 15Cholangiocarcinoma 15Gastrointestinal Neoplasms 14Liver Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Breast Neoplasms 12Unspecified Adult Solid Tumor, Protocol Specific 11Esophageal Squamous Cell Carcinoma 11Bile Duct Neoplasms 10Recurrence 9Peritoneal Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Ovarian Neoplasms 8Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Appendiceal Neoplasms 5Advanced Gastric Cancer 5

Interventions

folfirinox 2Oxaliplatin 2Irinotecan 2devimistat 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Pancreatic Cancer Metastatic × Oxaliplatin × Clear all
NCT04469556 2026-02-20

PASS-01

University Health Network, Toronto

Phase 2 Completed
150 enrolled
Gastrointestinal

Pancreatic Cancer Metastatic

NCT03504423 2023-01-03

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Cornerstone Pharmaceuticals

Phase 3 Completed
528 enrolled 11 charts
Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡